NEW YORK, Nov. 28, 2022 /PRNewswire/ — The multiple myeloma drugs market size is estimated to grow by USD 6,419.94 million during 2021-2026, at a CAGR of 5.9%. The growth of the market will be driven by the growing incidence of multiple myeloma. Furthermore, the emergence of nanomedicine platforms is expected to boost market growth.
The report extensively covers the Multiple myeloma drugs market segmentation by therapy (targeted therapy, biologic therapy, chemotherapy, and others), distribution channel (hospital pharmacy, retail pharmacy, and e-pharmacy), and geography (North America, Europe, Asiaand Rest of the World (ROW). Request A Free Sample Report
The growing competition in the market is compelling vendors to adopt various growth strategies such as promotional activities and spending on advertisements to improve the visibility of their services. Some vendors are also adopting inorganic growth strategies such as M&As to remain competitive. in the
- Amgen Inc.
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Bristol Myers Squibb Co.
- Cipla Ltd.
- Daiichi Sankyo Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Fresenius SE and Co. KGaA
- GlaxoSmithKline Plc
- Johnson and Johnson
- Merck and Co. Inc.
- Novartis AG
- Amgen Inc.: The company offers multiple myeloma drugs such as Kyprolis.
- AbbVie Inc.: The company offers multiple myeloma drugs such as Vysis 13q34 SpectrumGreen FISH Probe Kit.
- Amgen Inc.: The company offers multiple myeloma drugs such as Kyprolis.
For detailed insights about product offerings and the growth strategies adopted by vendors, buy the report.
North America is estimated to account for 36% of the market’s growth during the forecast period. The growing prevalence of various cancer indications, including multiple myeloma and non-Hodgkin’s lymphoma is driving the growth of the regional market. The market in North America is further benefited from the availability and high sales of approved multiple myeloma drugs. The patent expiry of a major drug brand has resulted in the development of generic versions of the drug by various large- and mid-sized pharmaceutical vendors in the region. This is Contributing to the growth of the multiple myeloma drugs market in North America.
The targeted therapy segment is estimated to contribute significantly to the global market’s growth during the forecast period. The increasing demand for targeted therapies is driven by the efficacy of the therapy in blocking the action of a substance in myeloma cells that disrupt proteins. This action helps in killing the myeloma cells. Also, the increasing number of drug approvals for the treatment of multiple myeloma is fueling the growth of the segment.
Additionally, recent approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. – Download a free sample report
What are the key data covered in this multiple myeloma drugs market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the multiple myeloma drugs market between 2023 and 2027
- Precise estimation of the size of the multiple myeloma drugs market size and its contribution of the market in focus to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the multiple myeloma drugs market industry across APAC, North America, Europe, Middle East and Africaand South America
- Thorough analysis of the market’s competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of multiple myeloma drugs market vendors
Technavio’s library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our “Basic Plan” at just USD 5,000 and get lifetime access to Technavio Insights
Related Reports:
Compounding Pharmacy Market by Product and Geography – Forecast and Analysis 2022-2026: The compounding pharmacy market share is expected to increase by USD 1.5 billion From 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 2.15%.
Proteasome Inhibitors Market by Product and Geography – Forecast and Analysis 2022-2026: According to Technavio’s analyst, the proteasome inhibitors market size is expected to be valued at USD 2.20 billion by 2026 with a CAGR of 7.4%.
|
Multiple Myeloma Drugs Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
167 |
|
base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.9% |
|
Market growth 2023-2027 |
USD 6419.94 million |
|
Market structure |
Fragmented |
|
YoY growth (%) |
5.76 |
|
Regional analysis |
North America, Europe, Asia, and Rest of the World (ROW) |
|
Performing market contribution |
North America at 36% |
|
Key countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann … |
